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Abstract. Brain metastases are a major cause of morbidity and 
mortality in breast cancer. The aim of the current study was 
to evaluate the prediction of brain metastases based on serum 
S100B and human epidermal growth factor receptor 2 (HER2). 
A total of 107 breast cancer patients were included in the 
current study from two prospective cohort studies with either 
elevated serum HER2 levels >15 ng/ml or brain metastases 
verified by magnetic resonance imaging (MRI) or computer 
tomography (CT). Following the exclusion of six patients, the 
remaining 101 patients were divided into two groups: Group 0 
(n=55), patients with normal MRI results; and group 1 (n=46), 
patients with brain metastases. The levels of serum S100B and 
HER2 in the two groups were analyzed prior to MRI or CT 
of the brain, and no significant differences were identified in 
the serum HER2 (P=0.060) or S100B levels (P=0.623) between 
the groups. The univariate analysis of prognostic factors for 
brain metastases showed a significant correlation with systemic 
disease (P<0.001), axillary lymph node metastases (P=0.001) 
and serum HER2 >30 ng/ml (P=0.002). Only systemic disease 
(P<0.001) remained statistically significant in the multivariate 
analysis. In conclusion, serum levels of S100B and HER2 did not 
predict the risk of brain metastases. In the multivariate analysis, 
brain metastases were only found to correlate with systemic 
disease. However, in the univariate analysis, serum HER2 levels 
>30 ng/ml were identified to correlate with increased risk of 
brain metastases, which calls for further investigation.
Introduction
Breast cancer is the leading malignant disease among females 
in the industrialized world. Although its incidence has increased 
over the past decade, there has been a significant decline in 
mortality from the disease in Denmark, possibly due to advances 
in screening programs, surgical techniques and adjuvant treat-
ment (1). Despite this progress, a significant number of females 
experience systemic spread of the disease. Brain metastases, in 
particular, remain a major cause of morbidity and mortality.
The subset of patients with overexpression of human 
epidermal growth factor receptor 2 (HER2) has been reported 
to have a high incidence of brain metastases (25-36%), even 
following adjuvant treatment with trastuzumab. Risk factors for 
the development of brain metastases in these patients include, 
estrogen receptor (ER)-negative tumor tissue, liver metastases, 
tissue HER2‑positive disease and age <50 years (2‑4).
At present, breast cancer patients are only evaluated for 
brain metastases in cases of symptom presentation and the use 
of magnetic resonance imaging (MRI) for the early diagnosis 
of subclinical brain metastases remains controversial (5). 
Miller et al found no improvement in overall survival among 
patients with brain metastases detected by screening (6). 
However, Niwińska et al demonstrated that whole brain radio-
therapy reduced the risk of mortality due to progression within 
the brain from 48 to 16%, comparing symptomatic brain 
metastases with occult brain metastases detected by MRI 
screening (7). However, there was no difference in overall 
survival between the two groups of patients.
Overexpression of the HER2 protein and/or amplification of 
the HER2 gene is detected in 15-20% of breast cancer tumors, 
leading to increased tumor cell proliferation, and is associated 
with aggressive tumor behavior and poor prognosis (8,9). In 
addition, HER2 overexpression and/or amplification predicts 
the effect of HER2-targeted therapeutics, including trastu-
zumab (Herceptin®) and lapatinib (Tyverb®) in metastatic and 
adjuvant settings (10-12).
HER2 (neu, ErbB2 or p185HER2) is a tyrosine kinase 
receptor in the HER family, which includes HER1 (EGFR), 
HER2, HER3 and HER4. The HER2 gene is located on 
chromosome 17 and encodes HER2, which is a 185‑kDa 
glycoprotein composed of an intracellular tyrosine kinase 
domain, a transmembrane domain and an extracellular domain 
with an unknown ligand (13). Activation of the HER2 pathway 
is presumably driven by heterodimerization of HER2 with 
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HER1, HER3 or HER4 and the subsequent activation of the 
downstream pathway (14).
The extracellular domain may be cleaved and measured in 
serum as ‘serum HER2’ by an enzyme-linked immunosorbent 
assay (15). The two most common assays used for moni-
toring serum HER2, HER2/neu ELISA (Oncogene Science, 
Cambridge, MA, USA) and ADVIA Centaur Serum HER2/
neu assay (Siemens Healthcare Diagnostics, Deerfield, IL, 
USA), have a reference cut‑off of 15 ng/ml (16). Carney et al 
demonstrated elevated serum HER2 in 18% (0‑38%) of 
patients with primary breast cancer and in 46% (23‑80%) 
of patients with metastatic breast cancer (17). A number of 
studies have reported a correlation between elevated levels 
of serum HER2 and clinical outcome (18‑22). In addition, 
specific studies have reported increasing serum HER2 levels 
prior to the relapse of breast cancer. However, the potential 
clinical implications associated with these observations 
remain to be shown (23-25).
S100B is a calcium binding protein specific to nervous 
tissue, including glial and Schwann cells. The protein has 
been revealed as a homo- or heterodimer consisting of two 
subunits (A and B) and S100B includes S100BB and S100AB. 
Depending on the concentration, S100B stimulates neurite 
outgrowth, survival of neurons or the expression of inflamma-
tory cytokines and induces apoptosis (26). Since S100B is a 
relatively small protein (9‑13 kDa), it has been hypothesized to 
pass through the intact blood-brain barrier. However, elevated 
S100B is only measured in serum under pathological condi-
tions that also compromise the blood-brain barrier. Serum 
S100B is measured by immunoassays; however, as there is 
no established cut-off, it is currently being determined which 
commercial S100B assays are more accurate (27,28). Yoon et 
al measured serum S100B in 74 healthy controls by the Elecsys 
S100 Immunoassay. The authors found a reference value for 
the 95th percentile of 0.12 µg/l, which is in accordance with 
the cut-off of 0.105 µg/l reported by the manufacturer (29).
The clinical utility of S100B has been evaluated in 
various studies, indicating a correlation between increased 
serum S100B and poorer outcome in traumatic brain injury 
and subarachnoid hemorrhage. A small study of 20 glioma 
patients by Vos et al demonstrated a significantly shorter 
median survival (25 vs. 38 months) in patients with serum 
S100B levels >0.09 µg/l (30). A large retrospective multi-
center study of 692 malignant melanoma patients found 
that elevated serum S100B correlated with inferior overall 
survival, but only in the univariate analysis (31). Serum 
S100B has also been evaluated as a screening tool for asymp-
tomatic brain metastases in 38 newly diagnosed non‑small 
cell lung cancer patients. The study identified elevated serum 
S100B (0.28±0.19 µg/l) in all 7 patients with brain metastases 
identified by MRI (32).
At present, no studies have examined the association 
between elevated serum S100B and brain metastases or the 
use of serum S100B as a screening tool for brain metastases 
in breast cancer. Therefore, it is important to clarify whether 
elevated serum S100B alone or together with serum HER2 
correlates with the incidence of brain metastases to identify 
patients for later intervention studies testing the clinical effect 
of early HER2-targeted treatment and radiotherapy. The aim 
of the present study was to address this issue.
Patients and methods
Study population and patient samples. Two cohorts of patients 
were obtained from two prospective studies (TL and VSL) 
performed at a single center cancer hospital (Vejle Hospital, 
Denmark). Serum HER2 levels were analyzed every 6 months 
during routine follow‑up after primary surgery for stage I‑IIIA 
breast cancer or stage IV metastatic breast cancer in a total 
of 1,308 patients. Patients provided written informed consent. 
The two studies were approved by the Regional Scientific 
Ethical Committee for Southern Denmark (project nos. 
S‑VF‑20040017 and S‑VF‑20040101).
Sixty-six patients with elevated serum HER2 levels 
>15 ng/ml during follow-up in the TL and VSL studies were 
included in the HER2‑MR protocol between 15 December, 
2010 and 12 April, 2012. Individuals who provided written 
informed consent and demonstrated no symptoms of brain 
metastases were eligible. Three patients were excluded due to 
protocol violation or serum HER2 levels <15 ng/ml at the time 
of inclusion (Fig. 1). The remaining 63 patients (40 patients in 
follow-up after primary surgery and 23 with systemic disease) 
underwent brain MRI and a computed tomography (CT) scan 
of the thorax and abdomen if in follow-up without relapse. The 
MRI scans were examined by two dedicated radiologists who 
reached agreement in all cases. The CT scans were examined 
in a routine setting. The protocol was approved by the Regional 
Scientific Ethical Committee for Southern Denmark (project 
no. S‑20100080).
Forty‑one patients (referred to as TL‑VSL‑BM), treated 
with radiotherapy for MRI‑ or CT‑verified brain metastases 
between 25 August, 2005 and 20 June, 2011, were included 
if the individual had received a serum HER2 test under the 
TL or VSL protocol within 3 months prior to being diagnosed 
with brain metastases. Three patients were excluded due to 
protocol violation, only ductal carcinoma in situ (DCIS) at the 
primary surgery or no serum remaining for analysis, leaving 
38 patients for further investigation. The additional analysis 
of serum S100B was also approved by the Regional Scientific 
Ethical Committee for Southern Denmark.
The remaining 101 patients were divided into two groups: 
Group 0, the control group (n=55), consisting of patients with 
normal MRI results and without symptoms of brain metastases; 
and group 1 (n=46; 38 TL‑VSL‑BM and 8 HER2‑MR patients), 
comprising patients with MRI‑ or CT‑verified meningeal and/or 
brain metastases (Fig. 1). The two groups were analyzed for 
serum HER2 and S100B levels prior to MRI or CT. Serum 
samples were stored in a local biobank at ‑80˚C.
Clinical and histopathological data. Histopathological data were 
obtained from the Danish Breast Cancer Cooperative Group 
(DBCG) and verified in the local database at the Department 
of Pathology, Vejle Hospital (Vejle, Denmark). Clinical patient 
data were obtained from the local electronic health record and 
complemented with data from the nationwide online electronic 
health record containing data from all Danish hospitals.
Biochemical and histopathological methods. Tissue HER2 
status was determined on paraffin‑embedded tumor tissue by 
immunohistochemistry (IHC) and fluorescence in situ hybrid-
ization (FISH). The tumors were considered to be HER2‑positive 
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when IHC3+ or IHC2+ with FISH ≥2. IHC analysis was assessed 
by HerceptestTM (DakoCytomation, Glostrup, Denmark), 
according to the manufacturer's instructions. IHC0 and IHC1+ 
were considered to represent HER2‑negative, whereas IHC3+ 
was defined as HER2‑positive. IHC2+ was considered to repre-
sent borderline and therefore, to determine HER2 status, the 
HER2 FISH pharmDxTM kit (DakoCytomation) was used. The 
threshold for HER2 amplification was a ratio of ≥2.0 between 
HER2 gene copy number and chromosome 17 centromere.
ER staining was performed on paraffin‑embedded tumor 
tissue using an anti‑human ER monoclonal antibody (clone 1D5; 
DakoCytomation) and visualized by the SuperSensitiveTM 
Polymer‑HRP IHC detection system (Biogenex, Fremont, CA, 
USA). Tumors with nuclei staining ≥10% were considered to 
represent ER-positive samples according to the contemporary 
DBCG guidelines.
Serum HER2 was measured using the ADVIA Centaur 
HER2 Immunoassay (Siemens Healthcare Diagnostics). The 
assay is an automated sandwich immunoassay using two 
monoclonal antibodies against the extracellular domain of 
HER2 to detect serum HER2 by direct chemiluminescent 
technology (33). The assay was controlled by an in-house 
serum pool at 8 ng/ml and two commercial controls (Siemens 
Healthcare Diagnostics) at 14 and 113 ng/ml. The inter-assay 
coefficients of variation (CV) of these controls were 10.7, 5.8 
and 4.6%, respectively.
Serum S100B was measured using the Elecsys S100 
Immunoassay (Roche Diagnostics GmbH, Mannheim, 
Germany). The assay is an automated sandwich immunoassay 
using two monoclonal antibodies against S100B forming 
a complex to be measured by direct chemiluminescent 
technology. Serum specimens were measured according to 
the manufacturer's instructions. The lower detection limit 
was 0.005 µg/l and the assay was controlled by commercial 
controls at 0.176 and 2.28 µg/l with an inter-assay CV between 
1.3 and 3.6%.
Statistical methods. Statistical analyses were performed 
using STATA 11 (Statacorp, College Station, TX, USA). 
Fisher's exact and Pearson's χ2 tests were used to compare 
categorical data. Continuous variables were compared using 
the Mann‑Whitney U test. A multivariate logistic regression 
analysis was used for the prognostic factors of brain metastases 
with dichotomized exposure variables. P<0.05 was considered 
to indicate a statistically significant difference.
Results
Patient characteristics. Final analysis included 101 patients 
divided into two groups: Group 0 (control group; n=55), patients 
with normal MRI results and no symptoms of brain metas-
tases; and group 1 (n=46), patients with MRI‑ or CT‑verified 
meningeal and/or brain metastases. Table I outlines the patient 
demographics and clinical characteristics of the two groups. 
Clinical prognostic factors were significantly better in group 0 
when compared with that of group 1 with regard to axillary 
nodal status (P=0.001) and systemic disease (P<0.001). In addi-
tion, an increased number of patients in group 1 compared with 
that of group 0 had systemic disease at the time of diagnosis. 
In the two groups, a high proportion of tissue HER2‑positive 
individuals were identified. Similarly, differences in adjuvant 
and palliative treatment were observed. As expected, a signifi-
cantly greater number of patients in group 1, when compared 
with that of group 0, received palliative treatment instead of 
adjuvant therapy; this was due to a greater number of patients 
in group 1 exhibiting systemic disease at the time of diagnosis.
Serum S100B. Fig. 2 demonstrates that no correlation was 
found between serum HER2 and S100B levels with a corre-
lation coefficient (r) of 0.077. Only four out of 63 patients 
from the HER2‑MR protocol had a serum S100B value 
exceeding the cut-off of 0.120 µg/l. Similarly, only two out of 
38 TL‑VSL‑BM patients had a serum S100B value exceeding 
the cut‑off. Table II demonstrates the sensitivity, specificity and 
positive and negative predictive value of serum S100B. A total 
of four out of 46 patients with brain metastases had a serum 
S100B level exceeding the cut-off of 0.120 µg/l, resulting in a 
sensitivity of 8.7% (95% CI, 3.2‑14.2%).
As presented in Fig. 3A, no significant differences were 
identified between serum S100B levels of the 46 patients in 
group 1 with brain metastases (median, 0.057 µg/l; range, 
0.021-0.367 µg/l) and the 55 patients in group 0 without 
brain metastases (median, 0.059 g/l; range, 0.020‑0.178 µg/l) 
(P=0.623). Similarly, no significant differences were identified 
between the 20 patients with brain metastases >20 mm and 
the 81 patients with smaller or no brain metastases (P=0.785; 
Fig. 3B). In addition, no significant differences were identified 
in serum S100B levels between the 59 patients with systemic 
disease (median, 0.054 µg/l) and the 42 patients without 
systemic disease (median, 0.062 µg/l) (P=0.241).
Serum HER2. No significant differences were identified in 
serum HER2 levels between the 46 patients in group 1 with 
brain metastases (median, 21.3 ng/ml; range, 7.6‑508.7 ng/ml) 
and the 55 patients in group 0 without brain metastases (median, 
16.5 ng/ml; range, 15.1‑207.8 ng/ml) (P=0.0598). This was also 
true when investigating the difference between the 20 patients 
Figure 1. Diagram outlining the exclusion of patients. HER2‑MR included 
66 patients who underwent brain MRI due to elevated serum HER2 
levels >15 ng/ml. TL‑VSL‑BM included 41 patients treated with radiotherapy 
for MRI‑ or CT‑ verified brain metastases. HER2, human epidermal growth 
factor receptor 2; MRI, magnetic resonance imaging; CT, computed tomog-
raphy; DCIS, ductal carcinoma in situ.
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with the largest brain metastases, >20 mm, compared with the 
81 patients with smaller or no brain metastases (P=0.8579).
The median value of serum HER2 was significantly higher in 
the 59 patients with systemic disease, 44 with and 15 without brain 
metastases (median, 21.5 ng/ml), compared with the 42 patients 
without systemic disease (median, 16.0 ng/ml)(P=0.0002). In 
addition, serum HER2 was significantly higher in the 31 patients 
with liver metastases (median, 30.4 ng/ml) than in the 70 patients 
without liver metastases (median, 16.7 ng/ml) (P=0.0011), and 
in the 56 tissue HER2‑positive patients (median, 19.6 ng/ml) 
compared with the 45 tissue HER2‑negative patients (median, 
16.0 ng/ml; P=0.0009) (data not shown).
Univariate and multivariate analysis of the prognostic factors 
of brain metastases. In the current study, a univariate analysis 
of the following variables was performed: Systemic disease 
(no/yes), age (<60/≥60 years‑old), tumor grade (1/2,3 and 
unknown, with unknown grade corresponding to systemic 
disease at diagnosis), tumor size (≤20/>20 mm), axillary lymph 
node metastases (no/yes), ER status (negative/positive), serum 
HER2 (<30/≥30 ng/ml) and serum S100B (<0.072/≥0.072 µg/l). 
For serum HER2 and S100B levels, the upper quadrant was 
compared with lower serum levels, as we hypothesized that the 
highest serum levels correlated with a poorer outcome and the 
possible differences, regardless of known cut-off values, were 
to be analyzed in the present study.
Table II. Serum S100B prior to CT or MRI of the brain.
Serum S100B Group 0a Group 1b Total
Elevated (>0.120 µg/l)   2   4   6
Normal (≤0.120 µg/l) 53 42 95
Total  55 46 101
aNormal MRI results (control group); bmeningeal and/or brain metas-
tases. CT, computed tomography; MRI, magnetic resonance imaging.
Table III. Univariate analysis of prognostic factors of brain 
metastasis.
Factor  P-value
Systemic disease, no/yes <0.001
Age, </≥60 years 0.522
Tumor grade, </≥grade 2a 0.054
Tumor size, ≤/>20 mm 0.590
Lymph nodes, ‑/+ 0.001
ER status, ‑/+ 0.656
HER2 IHC/FISH, ‑/+ 0.842
Serum HER2, </≥30 ng/ml 0.002
S100B, </≥0.072 µg/l 0.662
aGrade 2, 3 and unknown. ER, estrogen receptor; HER2, human epi-
dermal growth factor receptor 2; IHC, immunohistochemistry; FISH, 
fluroescence in situ hybridization.
Table I. Patient demographics and clinical characteristics.
  Group 0a Group 1b
  (n=55) (n=46)
  --------------------- ----------------------
Characteristic n % n % P-value
Age, years     
  <40    3 5.5   6 13.0 
  40‑59  35 63.6 23 50.0 
  ≥60 17 30.9 17 37.0 0.238
Type of surgery     
  Breast conserving 37 67.3 14 30.4 
  Mastectomy 12 21.8 16 34.8 
  Neoadjuvant chemo   3 5.5   1 2.2 
  Primary systemic BC   3 5.5 15 32.6 <0.001
Tumor type     
  Ductal 46 83.6 33 71.7 
  Lobular   1 1.8   2 4.3 
  Othersc   8 14.5 11 23.9 0.372
Tumor grade     
  1   9 16.4   2 4.3
  2 20 36.4 17  37.0
  3 18 32.7 15  32.6
  Unknownc   8 14.5 12 26.1 0.170
Tumor size     
  T1 22 40.0 16 34.8 
  T2 31 56.4 24 52.2 
  T3   2 3.6   6 13.0 0.254
Nodal status     
  N0 27 49.1   8 17.4 
  N1 15 27.3   9 19.6 
  N2   4 7.3 11 23.9 
  N3    4 7.3   7 15.2 
  Multiple on US/CTd   5 9.1 11 23.9 0.001
ER status     
  Negative 18 32.7 17  37.0 
  Positive 37 67.3 29  63.0 0.407
HER2 IHC/FISH     
  Negative 25 45.5 20 43.5 
  Positive 30 54.5 26 56.5 1.000
Systemic disease      
  No 40 72.7   2 4.3 
  Yes 15 27.3 44 95.7 <0.001
Groups were compared by Fisher's exact test. Bold P-value denotes 
statistical signficance. aNormal magnetic resonance imaging results 
(control group); bmeningeal and/or brain metastases; cmainly needle 
biopsy patients with primary systemic BC and no determination of 
tumor subtype; ddiagnosis of multiple pathological axillary lymph 
nodes by US or CT. Tumor size: T1, ≤20 mm; T2, >20 but ≤50 mm; 
T3, >50 mm. Nodal status: N0, 0 nodes; N1, 1‑3 nodes; N2, 4‑9 nodes; 
N3, ≥10 nodes. BC, breast cancer; US, ultrasound; CT, computed 
tomography; ER, estrogen receptor; HER2, human epidermal growth 
factor receptor 2; IHC, immunohistochemistry; FISH, fluroescence 
in situ hybridization.
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Table III presents the results of the univariate analysis, 
identifying systemic disease (P<0.001), axillary lymph node 
metastases (P=0.001) and serum HER2 (P=0.002) as statis-
tically significant prognostic factors of brain metastases. 
Levels of serum S100B were not statistically significant in the 
univariate analysis (P=0.662). 
The multivariate analysis was performed with the four 
variables from the univariate analysis that resulted in P<0.100. 
Only systemic disease (P<0.001) remained an independent 
prognostic factor of brain metastases, whereas tumor grade 
(P=0.095), axillary lymph node metastases (P=0.113) and 
serum HER2 (P=0.894) were not statistically significant in the 
multivariate analysis.
Discussion
In the current study, an extremely low number of patients had 
serum S100B levels exceeding the cut-off value. Subsequently, 
there was no difference in serum S100B between the patients 
with and without brain metastases. In addition, patients with 
the largest brain metastases, >20 mm and smaller or no brain 
metastases were not found to have different S100B serum 
levels. The comparison was based on the assumption that the 
largest brain metastases would cause the greatest damage to 
the brain tissue and the blood-brain barrier and subsequently 
have the highest levels of serum S100B. These observations 
may have several explanations.
Eigentler et al reported that serum S100B may be elevated in 
patients with brain metastases from malignant melanoma (31). 
However, in contrast to breast cancer, there is an overexpression 
of S100B in melanoma cells, which may explain the higher level 
of serum S100B in the brain metastases from malignant mela-
noma (34). In addition, Vos et al reported elevated serum S100B 
levels in patients with poorer outcome of primary gliomas of the 
brain as S100B is also expressed in gliomas (30). Korfias et al 
demonstrated elevated serum S100B in patients with traumatic 
head injury, where more diffuse damage to the glial cells is 
expected when compared with that of the damage caused by 
relatively slow growing metastases from breast cancer (26).
The current study did not find a significant difference in 
the levels of serum HER2 between patients with and without 
brain metastases; however, in the univariate analysis, serum 
HER2 levels >30 ng/ml were identified as a prognostic factor 
of brain metastases. These observations are consistent with 
a study by Sørensen et al reporting that the predictive value 
of serum HER2 to systemic relapse may be optimized with a 
cut-off value between 25 and 32 ng/ml in tissue HER2-negative 
and -positive patients, respectively (25). This may explain why 
no relapses in the group of patients were reported during the 
follow-up, as serum HER2 levels were only slightly >15 ng/ml.
The lack of differences in serum HER2 levels between 
patients with and without brain metastases may be the result 
of performing only one MRI screen during the current study in 
connection with elevated serum HER2 levels in the HER2‑MR 
protocol. Therefore, it is possible that the new, smallest brain 
metastases, not yet visible by MRI, were not detected, but 
elevated the serum HER2 levels. However, we would expect 
relapse in certain cases if there was a strong correlation, as 
the mean time from measurement of elevated serum HER2 
to MRI in this study was 71±58 days (standard deviation). In 
future studies, sequential MRI must be performed to identify a 
possible lead time from elevated serum HER2 levels to visible 
metastases by MRI, provided that the smallest brain metas-
tases have the capacity to cause elevated serum HER2.
In the HER2‑MR protocol, meningeal and/or brain metas-
tases were identified in eight out of 23 patients with known 
Figure 3. Correlation between (A) serum S100B and meningeal and/or brain 
metastases and (B) serum S100B and brain metastases ≥20 mm. Medians are 
presented as purple and yellow.
  A
  B
Figure 2. Correlation between serum HER2 and S100B (HER2‑MR, n=63; 
TL‑VSL‑BM, n=38; cut‑off, 0.120 µg/l).
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systemic disease and six of these had tissue HER2-positive 
disease. In future studies, when evaluating MRI screening for 
brain metastases, it may be advantageous to focus on the tissue 
HER2-positive patients with the highest serum HER2 levels in 
cases of otherwise stable systemic disease. Alternatively, all 
patients with tissue HER2-positive systemic disease must be 
offered MRI screening for brain metastases, as it is anticipated 
that, in the near future, improved targeted therapies are likely 
to be offered to these patients.
In conclusion, the present study demonstrates that quantita-
tive measurement of serum S100B and serum HER2 cannot 
be used to identify patients with an increased risk of brain 
metastases. However, in the univariate analysis, serum HER2 
levels >30 ng/ml were found to correlate with an increased risk 
of brain metastases, which warrants further investigation.
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